D
Deepali Suri
Publications - 4
Citations - 1199
Deepali Suri is an academic researcher. The author has contributed to research in topics: Ibrutinib & Chlorambucil. The author has an hindex of 3, co-authored 4 publications receiving 968 citations.
Papers
More filters
Journal ArticleDOI
Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia
Jan A. Burger,Alessandra Tedeschi,Paul M. Barr,Tadeusz Robak,Carolyn Owen,Paolo Ghia,Osnat Bairey,Peter Hillmen,Nancy L. Bartlett,Jianyong Li,David Simpson,Sebastian Grosicki,Stephen Devereux,Helen McCarthy,Steven Coutre,Hang Quach,Gianluca Gaidano,Zvenyslava Maslyak,Don A. Stevens,Ann Janssens,Fritz Offner,Jiří Mayer,Michael O'Dwyer,Andrzej Hellmann,Anna Schuh,Tanya Siddiqi,Aaron Polliack,Constantine S. Tam,Deepali Suri,Mei Cheng,Fong Clow,Lori Styles,Danelle F. James,Thomas J. Kipps +33 more
TL;DR: Ibrutinib was superior to chlorambucil in previously untreated patients with CLL or small lymphocytic lymphoma, as assessed by progression-free survival, overall survival, response rate, and improvement in hematologic variables.
Journal ArticleDOI
Randomized, multicenter, open-label, phase III study of the BTK inhibitor ibrutinib versus chlorambucil in patients 65 years or older with treatment-naive CLL/SLL (RESONATE-2, PCYC-1115-CA).
Jan A. Burger,Paolo Ghia,Aaron Polliack,Constantine S. Tam,Deepali Suri,Fong Clow,Silvija Kraljevic,Danelle F. James,Thomas J. Kipps +8 more
TL;DR: Findings support a phase III study of ibrutinib in older patients with treatment-naive CLL/SLL, and a randomized, multicenter, open label Ph 3 study comparing safety and efficacy of Ibrut inib vs. chlorambucil in TN patients aged >= 65 yrs with CLL /SLL.
Journal Article
Results from the international, randomized phase 3 study of ibrutinib versus chlorambucil in patients 65 Years and older with treatment-naive (TN) CLL/SLL (RESONATE-2 (TM))
Peter Hillmen,Alessandra Tedeschi,Paul M. Barr,Tadeusz Robak,Carolyn Owen,Paolo Ghia,Osnat Bairey,Nancy L. Bartlett,Jianyong Li,D. Simpson,Sebastian Grosicki,S. Devereux,Helen McCarthy,S. E. Coutre,Hang Quach,Gianluca Gaidano,Zvenyslava Maslyak,Don A. Stevens,A Janssens,Fritz Offner,Jiří Mayer,Michael O'Dwyer,Andrzej Hellmann,Anna Schuh,Tanya Siddiqi,A Pollack,Constantine S. Tam,Deepali Suri,Cathy Zhou,Fong Clow,Lori Styles,Danelle F. James,Thomas J. Kipps,Jan A. Burger +33 more
TL;DR: A randomized, open-label phase 3 trial to evaluate efficacy and safety of single-agent ibr vs clb in treatment-naive older pts with CLL/SLL found that ibr reduced the risk of progression or death by 91% and was consistent within subgroups including age ≥70 years, del11q, and unmutated IGHV .
Journal ArticleDOI
Results from the International, Randomized Phase 3 Study of Ibrutinib Versus Chlorambucil in Patients 65 Years and Older with Treatment-Naïve CLL/SLL (RESONATE-2TM)
Alessandra Tedeschi,Paul M. Barr,Tadeusz Robak,Carolyn Owen,Paolo Ghia,Osnat Bairey,Peter Hillmen,Nancy L. Bartlett,Jianyong Li,David Simpson,Sebastian Grosicki,Stephen Devereux,Helen McCarthy,Steven Coutre,Hang Quach,Gianluca Gaidano,Zvenyslava Maslyak,Don A. Stevens,Ann Janssens,Fritz Offner,Jiří Mayer,Michael O'Dwyer,Andrzej Hellmann,Anna Schuh,Tanya Siddiqi,Aaron Polliack,Constantine S. Tam,Michael J. Keating,Deepali Suri,Cathy Zhou,Fong Clow,Lori Styles,Danelle F. James,Thomas J. Kipps,Jan A. Burger +34 more
TL;DR: Byrd et al. as mentioned in this paper conducted a randomized, open-label phase 3 trial to evaluate efficacy and safety of single-agent ibr vs clb in treatment-naive older patients with CLL/SLL.